Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0P4BC
|
|||
Drug Name |
Disulfiram
|
|||
Synonyms |
Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Alcohol dependence [ICD-11: 6C40.2; ICD-10: F10.2; ICD-9: 303] | Approved | [1] | |
Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Investigative | [2] | ||
Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] | Investigative | [3] | ||
Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] | Investigative | [3] | ||
Therapeutic Class |
Antiviral Agents
|
|||
Company |
Odyssey Pharmaceuticals
|
|||
Structure |
Download2D MOL |
|||
Formula |
C10H20N2S4
|
|||
Canonical SMILES |
CCN(CC)C(=S)SSC(=S)N(CC)CC
|
|||
InChI |
1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
|
|||
InChIKey |
AUZONCFQVSMFAP-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 97-77-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
4833, 86944, 604564, 841760, 3134612, 7343344, 7847199, 8151985, 10321282, 10538921, 11111859, 11111860, 11363904, 11366466, 11369028, 11371250, 11374034, 11377190, 11466125, 11467245, 11484927, 11485729, 11488992, 11490221, 11492043, 11494824, 11533044, 11533307, 14720391, 14751553, 17405720, 22390447, 22391499, 24278722, 24888757, 26611716, 26680072, 26719650, 26747681, 26747682, 26753660, 26753661, 29222259, 46386898, 46487911, 46506008, 47216881, 47736606, 47810875, 48110561
|
|||
ChEBI ID |
CHEBI:4659
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | COVID-19 papain-like proteinase (PL-PRO) | Target Info | Inhibitor | [2] |
MERS-CoV papain-like proteinase (PL-PRO) | Target Info | Inhibitor | [3] | |
SARS-CoV papain-like proteinase (PL-PRO) | Target Info | Inhibitor | [3] |
References | Top | |||
---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
REF 2 | Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. | |||
REF 3 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.